Related references
Note: Only part of the references are listed.Metabolic syndrome in patients with prostate cancer undergoing androgen suppression
J. Morote et al.
ACTAS UROLOGICAS ESPANOLAS (2014)
Androgen-deprivation Therapy and Diabetes Control Among Diabetic Men with Prostate Cancer
Nancy L. Keating et al.
EUROPEAN UROLOGY (2014)
Terapia de privación de andrógenos y obesidad mórbida: ¿tienen en común el riesgo cardiovascular por síndrome metabólico?
S. Cleffi et al.
Actas Urologicas Espanolas (2013)
Continuous androgen-deprivation therapy increased risk for diabetes and fragility fractures in older men with prostate cancer
Julio Hajdenberg
ANNALS OF INTERNAL MEDICINE (2013)
The cardiovascular risk of gonadotropin releasing hormone agonists in men with prostate cancer: An unresolved controversy
Vincenza Conteduca et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2013)
Does Comorbidity Influence the Risk of Myocardial Infarction or Diabetes During Androgen-Deprivation Therapy for Prostate Cancer?
Nancy L. Keating et al.
EUROPEAN UROLOGY (2013)
Androgens, diabetes and prostate cancer
Mathis Grossmann et al.
ENDOCRINE-RELATED CANCER (2012)
Methods Guide for Authors of Systematic Reviews of Medical Tests: A Collaboration Between the Agency for Healthcare Research and Quality (AHRQ) and the Journal of General Internal Medicine
Gerald W. Smetana et al.
JOURNAL OF GENERAL INTERNAL MEDICINE (2012)
Short-term androgen deprivation therapy for patients with intermediate-risk prostate cancer undergoing dose-escalated radiotherapy: the standard of care?
Zachary S. Zumsteg et al.
LANCET ONCOLOGY (2012)
Polymorphisms in XPD and hOGG1 and Prostate Cancer Risk: A Meta-Analysis
Shimiao Zhu et al.
UROLOGIA INTERNATIONALIS (2012)
Androgen deprivation therapy through bilateral orchiectomy: increased metabolic risks
Juan-Jie Bo et al.
ASIAN JOURNAL OF ANDROLOGY (2011)
Changes in blood glucose and cholesterol levels due to androgen deprivation therapy in men with non-metastatic prostate cancer
Hassanabbas Z. Mohamedali et al.
CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL (2011)
POPULATION-BASED STUDY OF CARDIOVASCULAR MORTALITY AMONG PATIENTS WITH PROSTATE CANCER TREATED WITH RADICAL EXTERNAL BEAM RADIATION THERAPY WITH AND WITHOUT ADJUVANT ANDROGEN DEPRIVATION THERAPY AT THE BRITISH COLUMBIA CANCER AGENCY
Julian Kim et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2011)
Diabetes and Cardiovascular Disease During Androgen Deprivation Therapy: Observational Study of Veterans With Prostate Cancer
Nancy L. Keating et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2010)
Re: Parenteral Estrogen versus Combined Androgen Deprivation in the Treatment of Metastatic Prostatic Cancer: Part 2. Final Evaluation of the Scandinavian Prostatic Cancer Group (SPCG) Study No. 5
Jan Adolfsson
EUROPEAN UROLOGY (2009)
Impact of Androgen Deprivation Therapy on Cardiovascular Disease and Diabetes
Shabbir M. H. Alibhai et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Association between androgen-deprivation therapy and incidence of diabetes among males with prostate cancer
M. J. Lage et al.
UROLOGY (2007)
Androgen deprivation therapy does not impact cause-specific or overall survival in high-risk prostate cancer managed with brachytherapy and supplemental external beam
Gregory S. Merrick et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2007)
The rising prevalence of androgen deprivation among older American men since the advent of prostate-specific antigen testing: a population-based cohort study
Michael J. Barry et al.
BJU INTERNATIONAL (2006)
Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer
Nancy L. Keating et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy
Milena Braga-Basaria et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Insulin sensitivity during combined androgen blockade for prostate cancer
MR Smith et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2006)
Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy
S Basaria et al.
CANCER (2006)
Systematic reviews on rehabilitation interventions
HH Handoll
ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION (2006)
Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma
VB Shahinian et al.
CANCER (2005)
Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men
DE Laaksonen et al.
DIABETES CARE (2004)
Changes in fat and lean body mass during androgen-deprivation therapy for prostate cancer
MR Smith
UROLOGY (2004)
Towards evidence based medicine for paediatricians
B Phillips
ARCHIVES OF DISEASE IN CHILDHOOD (2004)
Measuring inconsistency in meta-analyses
JPT Higgins et al.
BMJ-BRITISH MEDICAL JOURNAL (2003)
Share Paper
